Methods for treating a disease in which Rho kinase is involved


Ontology type: sgo:Patent     


Patent Info

DATE

2010-12-21T00:00

AUTHORS

Masahiko Hagihara , Ken-ichi Komori , Hidetoshi Sunamoto , Hiroshi Nishida , Takeshi Matsugi , Tadashi Nakajima , Masakazu Hatano , Kazutaka Kido , Hideaki Hara

ABSTRACT

A method for treating a disease in which Rho kinase is involved. The method is carried out by administering to a patient in need thereof a pharmaceutically effective amount of a compound of the following formula or a pharmaceutically acceptable salt thereof: wherein the ring X is a benzene ring or a pyridine ring; R1 and R2 are hydrogen or alkyl or together form a cycloalkene ring; R3 is hydrogen, substituted alkyl, unsubstituted alkenyl, carboxyl or an ester or an amide thereof, amino or a cyano; R4 is hydrogen, hydroxyl, substituted or unsubstituted alkoxy, unsubstituted alkenyloxy, unsubstituted cycloalkyloxy, substituted or unsubstituted alkyl, unsubstituted alkenyl, unsubstituted cycloalkyl, amino, substituted or unsubstituted alkylamino, nitro, cyano or a monocyclic heterocycle; and R5 is a halogen atom or a hydrogen atom. More... »

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/2438", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "name": "Masahiko Hagihara", 
        "type": "Person"
      }, 
      {
        "name": "Ken-ichi Komori", 
        "type": "Person"
      }, 
      {
        "name": "Hidetoshi Sunamoto", 
        "type": "Person"
      }, 
      {
        "name": "Hiroshi Nishida", 
        "type": "Person"
      }, 
      {
        "name": "Takeshi Matsugi", 
        "type": "Person"
      }, 
      {
        "name": "Tadashi Nakajima", 
        "type": "Person"
      }, 
      {
        "name": "Masakazu Hatano", 
        "type": "Person"
      }, 
      {
        "name": "Kazutaka Kido", 
        "type": "Person"
      }, 
      {
        "name": "Hideaki Hara", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/40187", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014459412", 
          "https://doi.org/10.1038/40187"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/40187", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014459412", 
          "https://doi.org/10.1038/40187"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1021/cr950066q", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049163570"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1021/cr950066q", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049163570"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2010-12-21T00:00", 
    "description": "

A method for treating a disease in which Rho kinase is involved. The method is carried out by administering to a patient in need thereof a pharmaceutically effective amount of a compound of the following formula or a pharmaceutically acceptable salt thereof:

\"embedded
\nwherein the ring X is a benzene ring or a pyridine ring; R1 and R2 are hydrogen or alkyl or together form a cycloalkene ring; R3 is hydrogen, substituted alkyl, unsubstituted alkenyl, carboxyl or an ester or an amide thereof, amino or a cyano; R4 is hydrogen, hydroxyl, substituted or unsubstituted alkoxy, unsubstituted alkenyloxy, unsubstituted cycloalkyloxy, substituted or unsubstituted alkyl, unsubstituted alkenyl, unsubstituted cycloalkyl, amino, substituted or unsubstituted alkylamino, nitro, cyano or a monocyclic heterocycle; and R5 is a halogen atom or a hydrogen atom.\n

", "id": "sg:patent.US-7855222-B2", "keywords": [ "method", "disease", "rho-Associated Kinase", "patient", "compound", "formula", "salt", "wherein", "ring", "benzene ring", "pyridine", "hydrogen", "alkyl", "carboxyl", "ester", "amide", "amino", "hydroxyl", "heterocycle", "halogen atom", "hydrogen atom" ], "name": "Methods for treating a disease in which Rho kinase is involved", "recipient": [ { "id": "https://www.grid.ac/institutes/grid.419503.a", "type": "Organization" }, { "id": "https://www.grid.ac/institutes/grid.471314.4", "type": "Organization" } ], "sameAs": [ "https://app.dimensions.ai/details/patent/US-7855222-B2" ], "sdDataset": "patents", "sdDatePublished": "2019-04-18T10:06", "sdLicense": "https://scigraph.springernature.com/explorer/license/", "sdPublisher": { "name": "Springer Nature - SN SciGraph project", "type": "Organization" }, "sdSource": "s3://com-uberresearch-data-patents-target-20190320-rc/data/sn-export/402f166718b70575fb5d4ffe01f064d1/0000100128-0000352499/json_export_00145.jsonl", "type": "Patent" } ]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/patent.US-7855222-B2'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/patent.US-7855222-B2'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/patent.US-7855222-B2'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/patent.US-7855222-B2'


 

This table displays all metadata directly associated to this object as RDF triples.

84 TRIPLES      15 PREDICATES      38 URIs      29 LITERALS      2 BLANK NODES

Subject Predicate Object
1 sg:patent.US-7855222-B2 schema:about anzsrc-for:2438
2 schema:author N442846c44d694a01b10575815fa0220e
3 schema:citation sg:pub.10.1038/40187
4 https://doi.org/10.1021/cr950066q
5 schema:datePublished 2010-12-21T00:00
6 schema:description <p num="p-0001">A method for treating a disease in which Rho kinase is involved. The method is carried out by administering to a patient in need thereof a pharmaceutically effective amount of a compound of the following formula or a pharmaceutically acceptable salt thereof:</p><p num="p-0002"><chemistry id="CHEM-US-00001" num="00001"><img id="EMI-C00001" he="30.40mm" wi="57.74mm" file="US07855222-20101221-C00001.TIF" alt="embedded image" img-content="chem" img-format="tif"/><attachments><attachment idref="CHEM-US-00001" attachment-type="cdx" file="US07855222-20101221-C00001.CDX"/><attachment idref="CHEM-US-00001" attachment-type="mol" file="US07855222-20101221-C00001.MOL"/></attachments></chemistry><br/> wherein the ring X is a benzene ring or a pyridine ring; R<sup>1 </sup>and R<sup>2 </sup>are hydrogen or alkyl or together form a cycloalkene ring; R<sup>3 </sup>is hydrogen, substituted alkyl, unsubstituted alkenyl, carboxyl or an ester or an amide thereof, amino or a cyano; R<sup>4 </sup>is hydrogen, hydroxyl, substituted or unsubstituted alkoxy, unsubstituted alkenyloxy, unsubstituted cycloalkyloxy, substituted or unsubstituted alkyl, unsubstituted alkenyl, unsubstituted cycloalkyl, amino, substituted or unsubstituted alkylamino, nitro, cyano or a monocyclic heterocycle; and R<sup>5 </sup>is a halogen atom or a hydrogen atom. </p>
7 schema:keywords alkyl
8 amide
9 amino
10 benzene ring
11 carboxyl
12 compound
13 disease
14 ester
15 formula
16 halogen atom
17 heterocycle
18 hydrogen
19 hydrogen atom
20 hydroxyl
21 method
22 patient
23 pyridine
24 rho-Associated Kinase
25 ring
26 salt
27 wherein
28 schema:name Methods for treating a disease in which Rho kinase is involved
29 schema:recipient https://www.grid.ac/institutes/grid.419503.a
30 https://www.grid.ac/institutes/grid.471314.4
31 schema:sameAs https://app.dimensions.ai/details/patent/US-7855222-B2
32 schema:sdDatePublished 2019-04-18T10:06
33 schema:sdLicense https://scigraph.springernature.com/explorer/license/
34 schema:sdPublisher N9495896f82cf452a9f1aecea2fc86fdd
35 sgo:license sg:explorer/license/
36 sgo:sdDataset patents
37 rdf:type sgo:Patent
38 N08c5ef9a49ec49c387215ebea6d5de58 rdf:first Nc2a58c0807d541a381b0ad5cf0cbd7d8
39 rdf:rest Nfac87d7b545f4dc985486ffa60864761
40 N0b7031de5ce049ac9b658392afd28202 schema:name Masakazu Hatano
41 rdf:type schema:Person
42 N126d9ceea2b8461a8c9710d2bded8c4b rdf:first Nc5f5b978669f4ad48897df22158ce203
43 rdf:rest N2a1a83b5c5514cb1b08b625180214e8e
44 N23fcaa3aa21640cf95406cd0ebe1272e rdf:first Nc361baa956a84419a26e45137b7d941f
45 rdf:rest Nfe0acc2ff0ca41dea48965fcb8aba876
46 N2a1a83b5c5514cb1b08b625180214e8e rdf:first N4d0343ddf88644bcbdbec2ea975afb51
47 rdf:rest N08c5ef9a49ec49c387215ebea6d5de58
48 N442846c44d694a01b10575815fa0220e rdf:first N5b79fee6d9264eae861fd3627a41873f
49 rdf:rest N126d9ceea2b8461a8c9710d2bded8c4b
50 N471382fa043e4209aa0cd51d7276b50f schema:name Takeshi Matsugi
51 rdf:type schema:Person
52 N4d0343ddf88644bcbdbec2ea975afb51 schema:name Hidetoshi Sunamoto
53 rdf:type schema:Person
54 N5b79fee6d9264eae861fd3627a41873f schema:name Masahiko Hagihara
55 rdf:type schema:Person
56 N725929d8c77f4c83ac19be13650cf46c schema:name Hideaki Hara
57 rdf:type schema:Person
58 N744f20f59a4143388904dcd3a2b9c6fe rdf:first N9d95348232a44f10b3eb4a876c6bed6d
59 rdf:rest Ne98f079e28804e4ba0b294bab2422acc
60 N9495896f82cf452a9f1aecea2fc86fdd schema:name Springer Nature - SN SciGraph project
61 rdf:type schema:Organization
62 N9d95348232a44f10b3eb4a876c6bed6d schema:name Tadashi Nakajima
63 rdf:type schema:Person
64 Nc2a58c0807d541a381b0ad5cf0cbd7d8 schema:name Hiroshi Nishida
65 rdf:type schema:Person
66 Nc361baa956a84419a26e45137b7d941f schema:name Kazutaka Kido
67 rdf:type schema:Person
68 Nc5f5b978669f4ad48897df22158ce203 schema:name Ken-ichi Komori
69 rdf:type schema:Person
70 Ne98f079e28804e4ba0b294bab2422acc rdf:first N0b7031de5ce049ac9b658392afd28202
71 rdf:rest N23fcaa3aa21640cf95406cd0ebe1272e
72 Nfac87d7b545f4dc985486ffa60864761 rdf:first N471382fa043e4209aa0cd51d7276b50f
73 rdf:rest N744f20f59a4143388904dcd3a2b9c6fe
74 Nfe0acc2ff0ca41dea48965fcb8aba876 rdf:first N725929d8c77f4c83ac19be13650cf46c
75 rdf:rest rdf:nil
76 anzsrc-for:2438 schema:inDefinedTermSet anzsrc-for:
77 rdf:type schema:DefinedTerm
78 sg:pub.10.1038/40187 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014459412
79 https://doi.org/10.1038/40187
80 rdf:type schema:CreativeWork
81 https://doi.org/10.1021/cr950066q schema:sameAs https://app.dimensions.ai/details/publication/pub.1049163570
82 rdf:type schema:CreativeWork
83 https://www.grid.ac/institutes/grid.419503.a schema:Organization
84 https://www.grid.ac/institutes/grid.471314.4 schema:Organization
 




Preview window. Press ESC to close (or click here)


...